Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle intervention are unknown. This double-blind, placebo-controlled trial randomized (1:1) adults with body mass index ≥30 or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2023-11, Vol.29 (11), p.2909-2918
Hauptverfasser:	Wadden, Thomas A., Chao, Ariana M., Machineni, Sriram, Kushner, Robert, Ard, Jamy, Srivastava, Gitanjali, Halpern, Bruno, Zhang, Shuyu, Chen, Jiaxun, Bunck, Mathijs C., Ahmad, Nadia N., Forrester, Tammy
Format:	Artikel
Sprache:	eng
Schlagworte:	692/163/2743/393 692/699/317 Adult Adults Antidiabetics Biomedical and Life Sciences Biomedicine Body mass index Body size Body weight Body weight loss Cancer Research Diabetes mellitus Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method GIP protein GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Humans Hypoglycemic Agents Infectious Diseases Intervention Life Style Lifestyles Metabolic Diseases Molecular Medicine Neurosciences Obesity Obesity - drug therapy Overweight Overweight - therapy Placebos Polypeptides Randomization Standard error Weight control Weight Loss Weight reduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!